147 related articles for article (PubMed ID: 15448080)
1. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin.
van den Hoek AM; Voshol PJ; Karnekamp BN; Buijs RM; Romijn JA; Havekes LM; Pijl H
Diabetes; 2004 Oct; 53(10):2529-34. PubMed ID: 15448080
[TBL] [Abstract][Full Text] [Related]
2. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation.
van den Hoek AM; van Heijningen C; Schröder-van der Elst JP; Ouwens DM; Havekes LM; Romijn JA; Kalsbeek A; Pijl H
Diabetes; 2008 Sep; 57(9):2304-10. PubMed ID: 18544708
[TBL] [Abstract][Full Text] [Related]
3. Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats.
Vettor R; Zarjevski N; Cusin I; Rohner-Jeanrenaud F; Jeanrenaud B
Diabetologia; 1994 Dec; 37(12):1202-8. PubMed ID: 7895949
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet.
Parlevliet ET; de Leeuw van Weenen JE; Romijn JA; Pijl H
Am J Physiol Endocrinol Metab; 2010 Aug; 299(2):E318-24. PubMed ID: 20530733
[TBL] [Abstract][Full Text] [Related]
5. PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet.
van den Hoek AM; Heijboer AC; Corssmit EP; Voshol PJ; Romijn JA; Havekes LM; Pijl H
Diabetes; 2004 Aug; 53(8):1949-52. PubMed ID: 15277371
[TBL] [Abstract][Full Text] [Related]
6. Intracerebroventricular neuropeptide Y acutely influences glucose metabolism and insulin sensitivity in the rat.
Marks JL; Waite K
J Neuroendocrinol; 1997 Feb; 9(2):99-103. PubMed ID: 9041362
[TBL] [Abstract][Full Text] [Related]
7. Chronic central melanocortin-4 receptor antagonism and central neuropeptide-Y infusion in rats produce increased adiposity by divergent pathways.
Baran K; Preston E; Wilks D; Cooney GJ; Kraegen EW; Sainsbury A
Diabetes; 2002 Jan; 51(1):152-8. PubMed ID: 11756335
[TBL] [Abstract][Full Text] [Related]
8. Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue.
Sainsbury A; Cusin I; Doyle P; Rohner-Jeanrenaud F; Jeanrenaud B
Diabetologia; 1996 Mar; 39(3):353-6. PubMed ID: 8721783
[TBL] [Abstract][Full Text] [Related]
9. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle.
Zarjevski N; Cusin I; Vettor R; Rohner-Jeanrenaud F; Jeanrenaud B
Diabetes; 1994 Jun; 43(6):764-9. PubMed ID: 8194661
[TBL] [Abstract][Full Text] [Related]
10. Acute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in mice.
Geerling JJ; Wang Y; Havekes LM; Romijn JA; Rensen PC
PLoS One; 2013; 8(2):e55217. PubMed ID: 23460782
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of hypothalamic neuropeptide Y gene expression by insulin.
Schwartz MW; Sipols AJ; Marks JL; Sanacora G; White JD; Scheurink A; Kahn SE; Baskin DG; Woods SC; Figlewicz DP
Endocrinology; 1992 Jun; 130(6):3608-16. PubMed ID: 1597158
[TBL] [Abstract][Full Text] [Related]
12. Intraportal administration of neuropeptide Y and hepatic glucose metabolism.
Nishizawa M; Shiota M; Moore MC; Gustavson SM; Neal DW; Cherrington AD
Am J Physiol Regul Integr Comp Physiol; 2008 Apr; 294(4):R1197-204. PubMed ID: 18234742
[TBL] [Abstract][Full Text] [Related]
13. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production.
den Boer MA; Voshol PJ; Kuipers F; Romijn JA; Havekes LM
Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1360-4. PubMed ID: 16849628
[TBL] [Abstract][Full Text] [Related]
14. Interaction between adrenal glucocorticoids and parasympathetic activation in mediating hyperinsulinaemia during long-term central neuropeptide Y infusion in rats.
Sainsbury A; Wilks D; Cooney GJ
Diabetologia; 2000 Jul; 43(7):859-65. PubMed ID: 10952458
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.
Lucidi P; Rossetti P; Porcellati F; Pampanelli S; Candeloro P; Andreoli AM; Perriello G; Bolli GB; Fanelli CG
Diabetes; 2010 Jun; 59(6):1349-57. PubMed ID: 20299466
[TBL] [Abstract][Full Text] [Related]
16. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.
Lewis GF; Uffelman KD; Szeto LW; Weller B; Steiner G
J Clin Invest; 1995 Jan; 95(1):158-66. PubMed ID: 7814610
[TBL] [Abstract][Full Text] [Related]
17. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice.
Parlevliet ET; Schröder-van der Elst JP; Corssmit EP; Picha K; O'Neil K; Stojanovic-Susulic V; Ort T; Havekes LM; Romijn JA; Pijl H
J Pharmacol Exp Ther; 2009 Jan; 328(1):240-8. PubMed ID: 18849357
[TBL] [Abstract][Full Text] [Related]
18. Effects of intravenous neuropeptide Y on insulin secretion and insulin sensitivity in skeletal muscle in normal rats.
Vettor R; Pagano C; Granzotto M; Englaro P; Angeli P; Blum WF; Federspil G; Rohner-Jeanrenaud F; Jeanrenaud B
Diabetologia; 1998 Nov; 41(11):1361-7. PubMed ID: 9833945
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system neuropeptide Y signaling modulates VLDL triglyceride secretion.
Stafford JM; Yu F; Printz R; Hasty AH; Swift LL; Niswender KD
Diabetes; 2008 Jun; 57(6):1482-90. PubMed ID: 18332095
[TBL] [Abstract][Full Text] [Related]
20. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.
Cummings MH; Watts GF; Umpleby AM; Hennessy TR; Kelly JM; Jackson NC; Sönksen PH
Diabetes; 1995 Sep; 44(9):1059-65. PubMed ID: 7657029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
